Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track RCUS with free AI briefings, catalyst countdowns, and dilution alerts.

RCUS · Arcus Biosciences, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$694M Cash on Hand
20.1mo Cash Runway
Follow RCUS by email Get an email when RCUS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about RCUS, unsubscribe in one click. Privacy

📣 What RCUS Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Domvanalimab Non-small Cell Lung Cancer Phase 3 · NCT05502237 Active not recruiting
Nab-paclitaxel Non-small Cell Lung Cancer Phase 3 · NCT05502237 Active not recruiting
Casdatifan (AB521) Metastatic Clear Cell Renal Cell Carcinoma Phase 3 · NCT07011719 Recruiting
Quemliclustat (AB680) Metastatic Pancreatic Ductal Adenocarcinoma Phase 3 · NCT06608927 Active not recruiting
Zimberelimab Non-small Cell Lung Cancer Phase 3 · NCT05502237 Active not recruiting
Sacituzumab Govitecan Lung Cancer Phase 2 · NCT05633667 Active not recruiting
Platinum Doublet Advanced Non-Small Cell Lung Cancer Phase 2 · NCT05676931 Active not recruiting
Perenostobart (SRF617) Metastatic Castration-resistant Prostate Cancer Phase 2 · NCT05177770 Terminated
Irinotecan Borderline Resectable Pancreatic Adenocarcinoma Phase 1/2 · NCT05688215 Recruiting
m-FOLFOX-6 regimen Metastatic Colorectal Cancer Phase 1/2 · NCT04660812 Completed
modified FOLFIRINOX (Treatment Group C) Pancreatic Ductal Adenocarcinoma Phase 2 · NCT06048484 Recruiting
Etrumadenant Lung Cancer Phase 2 · NCT05633667 Active not recruiting
Sotigalimab (APX005M) Pancreatic Cancer Phase 1/2 · NCT05419479 Suspended
FOLFOX regimen Rectal Cancer Phase 2 · NCT05024097 Recruiting
FOLFIRI Pancreatic Cancer Phase 1/2 · NCT05419479 Suspended
Volrustomig Advanced Clear Cell Renal Cell Carcinoma Phase 1 · NCT07000149 Active not recruiting

Also used in these trials (approved or third-party drugs, not RCUS's own candidates): Cisplatin, Gemcitabine Hydrochloride, Fluorouracil, Leucovorin, Durvalumab, Carboplatin, Capecitabine, Nivolumab, Oxaliplatin, Paclitaxel, Pembrolizumab, Cabozantinib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

RCUS holds $694M in cash and short-term investments (as of Sep 30, 2026) and burns about $103.5M/quarter from operations, an estimated runway of 20.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 22 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RCUS files for a raise →

👥 Who Owns RCUS

Insiders 3.8% Other 5%+ holders 21.8% Institutions (344 holders) 67.6% Public and other holders 6.8%
HolderTypeShares% of sharesAs of
Gilead Sciences, Inc. 5%+ holder (13D) 31,424,760 21.82% 2026-08-05
BlackRock, Inc. Institution (13G, 5%+) 12,736,927 8.85% 2025-12-31
Terry J Rosen
Chief Executive Officer, Director · +315,000 options
Insider 2,236,409 1.55% 2026-01-23
Juan C. Jaen
President · +126,000 options
Insider 1,200,531 0.83% 2026-07-09
Yasunori Kaneko
Director · +16,900 options
Insider 957,955 0.67% 2026-06-11
Jennifer Jarrett
Chief Operating Officer · +206,583 options
Insider 224,024 0.16% 2026-01-23
Carolyn C. Tang
General Counsel · +96,000 options
Insider 184,607 0.13% 2026-06-11
Kathryn E Falberg
Director · +16,900 options
Insider 176,406 0.12% 2026-06-11
Richard Markus
Chief Medical Officer · +96,000 options
Insider 89,647 0.06% 2026-01-23
II Robert C. Goeltz
Chief Financial Officer · +96,000 options
Insider 84,161 0.06% 2026-05-11
David L. Lacey
Director · +16,900 options
Insider 76,652 0.05% 2026-06-11
Antoni Ribas
Director · +16,900 options
Insider 52,853 0.04% 2026-06-11

Share count 143,990,614 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full RCUS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RCUS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.